- Home
- NKX vs RIGL Comparison
NKX vs RIGL Comparison
Compare NKX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKX
- RIGL
- Stock Information
- Founded
- NKX 2002
- RIGL 1996
- Country
- NKX United States
- RIGL United States
- Employees
- NKX N/A
- RIGL N/A
- Industry
- NKX Finance/Investors Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NKX Finance
- RIGL Health Care
- Exchange
- NKX Nasdaq
- RIGL Nasdaq
- Market Cap
- NKX 605.4M
- RIGL 366.5M
- IPO Year
- NKX N/A
- RIGL 2000
- Fundamental
- Price
- NKX $12.75
- RIGL $19.91
- Analyst Decision
- NKX
- RIGL Buy
- Analyst Count
- NKX 0
- RIGL 5
- Target Price
- NKX N/A
- RIGL $36.80
- AVG Volume (30 Days)
- NKX 109.3K
- RIGL 219.4K
- Earning Date
- NKX 01-01-0001
- RIGL 03-04-2025
- Dividend Yield
- NKX 4.37%
- RIGL N/A
- EPS Growth
- NKX N/A
- RIGL N/A
- EPS
- NKX N/A
- RIGL 0.99
- Revenue
- NKX N/A
- RIGL $179,278,000.00
- Revenue This Year
- NKX N/A
- RIGL $14.19
- Revenue Next Year
- NKX N/A
- RIGL $13.10
- P/E Ratio
- NKX N/A
- RIGL $20.64
- Revenue Growth
- NKX N/A
- RIGL 54.71
- 52 Week Low
- NKX $9.78
- RIGL $7.48
- 52 Week High
- NKX $12.00
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- NKX 48.68
- RIGL 45.28
- Support Level
- NKX $12.53
- RIGL $18.44
- Resistance Level
- NKX $12.81
- RIGL $20.88
- Average True Range (ATR)
- NKX 0.13
- RIGL 1.55
- MACD
- NKX -0.01
- RIGL -0.24
- Stochastic Oscillator
- NKX 42.31
- RIGL 29.05
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.